Fresenius Kabi Recalls Tyenne® (tocilizumab-aazg) Injection Vials Due to Glass Particles

Fresenius Kabi has issued a nationwide recall of specific lots of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL vials due to the presence of glass particles. The FDA published this recall, noting that healthcare providers and consumers should immediately notify customers who may have received the affected product. Patients experiencing any problems related to this drug product are advised to contact their physician or healthcare provider.